G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
Koichi Takahashi,Koichi Takahashi,Feng Wang,Hagop M. Kantarjian,Denaha J. Doss,Kanhav Khanna,Erika Thompson,Li Zhao,Keyur P. Patel,Sattva S. Neelapu,Curtis Gumbs,Carlos E. Bueso-Ramos,Courtney D. DiNardo,Simona Colla,Farhad Ravandi,Jianhua Zhang,Xuelin Huang,Xifeng Wu,Felipe Samaniego,Guillermo Garcia-Manero,P. Andrew Futreal +20 more
TL;DR: Pre-leukemic clonal hematopoiesis is frequently detected in patients with t-MNs at the time of their primary cancer diagnosis and before patients were exposed to chemotherapy/radiation therapy.
Journal ArticleDOI
K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis.
Yumin Hu,Weiqin Lu,Gang Chen,Peng Wang,Zhao Chen,Yan Zhou,Marcia A. Ogasawara,Dunyaporn Trachootham,Dunyaporn Trachootham,Li Feng,Helene Pelicano,Paul J. Chiao,Michael J. Keating,Guillermo Garcia-Manero,Peng Huang +14 more
TL;DR: This study suggests that induction of mitochondrial dysfunction is an important mechanism by which K-rasG12V causes metabolic changes and ROS stress in cancer cells, and promotes tumor development.
Journal ArticleDOI
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Stefan Faderl,Deborah A. Thomas,Susan O'Brien,Guillermo Garcia-Manero,Hagop M. Kantarjian,Francis J. Giles,Charles Koller,Alessandra Ferrajoli,Srdan Verstovsek,Barbara Pro,Michael Andreeff,Miloslav Beran,Jorge E. Cortes,William G. Wierda,Ngoc Tran,Michael J. Keating +15 more
TL;DR: The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses.
Journal ArticleDOI
DNA Methylation Changes after 5-Aza-2′-Deoxycytidine Therapy in Patients with Leukemia
Allen S. Yang,Ketan Doshi,Sang-Woon Choi,Joel B. Mason,Rajan Mannari,Vazganush Gharybian,Rene Luna,Asif Rashid,Lanlan Shen,Marcos R. Estecio,Hagop M. Kantarjian,Guillermo Garcia-Manero,Jean Pierre J. Issa +12 more
TL;DR: D dose-dependent hypomethylation after decitabine at low doses is shown, which has been shown previously to result in a reduced response rate, and increasing the dose was not accompanied by further hypometHylation.
Journal ArticleDOI
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.
Joanne I. Hsu,Joanne I. Hsu,Tajhal Dayaram,Ayala Tovy,Etienne De Braekeleer,Etienne De Braekeleer,Mira Jeong,Feng Wang,Jianhua Zhang,Timothy P. Heffernan,Sonal Gera,Jeffrey J. Kovacs,Joseph R. Marszalek,Christopher A. Bristow,Yuanqing Yan,Guillermo Garcia-Manero,Hagop M. Kantarjian,George S. Vassiliou,George S. Vassiliou,P. Andrew Futreal,Lawrence A. Donehower,Koichi Takahashi,Margaret A. Goodell,Margaret A. Goodell +23 more
TL;DR: It is found that mutations in PPM1D (protein phosphatase Mn2+/Mg2+-dependent 1D), a DNA damage response regulator that is frequently mutated in CH, were present in one-fifth of patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome and strongly correlated with cisplatin exposure.